David Osborne - Arcutis Biotherapeutics Chief Officer
| ARQT Stock | USD 12.25 0.52 4.07% |
Insider
David Osborne is Chief Officer of Arcutis Biotherapeutics
| Age | 63 |
| Address | 3027 Townsgate Road, Westlake Village, CA, United States, 91361 |
| Phone | 805 418 5006 |
| Web | https://www.arcutis.com |
David Osborne Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Osborne against Arcutis Biotherapeutics stock is an integral part of due diligence when investing in Arcutis Biotherapeutics. David Osborne insider activity provides valuable insight into whether Arcutis Biotherapeutics is net buyers or sellers over its current business cycle. Note, Arcutis Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Arcutis Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Osborne over a year ago Conversion by David Osborne of 63332 shares of NLIGHT |
Arcutis Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3114) % which means that it has lost $0.3114 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9231) %, meaning that it created substantial loss on money invested by shareholders. Arcutis Biotherapeutics' management efficiency ratios could be used to measure how well Arcutis Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.86 in 2024. Total Current Liabilities is likely to drop to about 23.4 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 260.7 M in 2024Similar Executives
| Showing other executives | INSIDER Age | ||
| Friedrich MD | Iovance Biotherapeutics | 57 | |
| Michael MBA | Syndax Pharmaceuticals | 53 | |
| Igor Bilinsky | Iovance Biotherapeutics | 51 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Carrie MD | Zentalis Pharmaceuticals Llc | 54 | |
| MSc MBA | Inozyme Pharma | 52 | |
| MS MBA | Inozyme Pharma | 47 | |
| Ryan Brown | Sarepta Therapeutics | 46 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Howard MBA | Iovance Biotherapeutics | 64 | |
| Kevin Bunker | Zentalis Pharmaceuticals Llc | 52 | |
| Keith CPA | Syndax Pharmaceuticals | 53 | |
| Briggs MD | Syndax Pharmaceuticals | 64 | |
| Kimberly MD | Zentalis Pharmaceuticals Llc | 55 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Meena Rao | Zentalis Pharmaceuticals Llc | N/A | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Peter BSc | Syndax Pharmaceuticals | 55 | |
| Richard Heyman | Syndax Pharmaceuticals | 67 | |
Management Performance
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.31 |
Arcutis Biotherapeutics Leadership Team
Elected by the shareholders, the Arcutis Biotherapeutics' board of directors comprises two types of representatives: Arcutis Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcutis. The board's role is to monitor Arcutis Biotherapeutics' management team and ensure that shareholders' interests are well served. Arcutis Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcutis Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Turney, VP Operations | ||
| Todd Edwards, Executive Officer | ||
| Eric McIntyre, Head Relations | ||
| Ayisha Jeter, Head Access | ||
| David Osborne, Chief Officer | ||
| Bethany Dudek, Chief Officer | ||
| JD Esq, General VP | ||
| Todd Tucker, Vice Resources | ||
| Rajvir Madan, Chief Officer | ||
| Amanda Sheldon, Head Communications | ||
| Aleen Hosdaghian, Vice Marketing | ||
| Courtney Barton, VP Officer | ||
| Matthew Moore, Senior Officer | ||
| Scott Burrows, CFO Officer | ||
| Bhaskar Chaudhuri, CoFounder Director | ||
| Latha Vairavan, Vice Controller | ||
| Kent Taylor, Senior Sales | ||
| David Topper, Senior Officer | ||
| Todd MA, CEO President | ||
| John CPA, Interim Officer |
Arcutis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcutis Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 1.37 B | ||||
| Shares Outstanding | 117.05 M | ||||
| Shares Owned By Insiders | 2.14 % | ||||
| Shares Owned By Institutions | 97.86 % | ||||
| Number Of Shares Shorted | 23.53 M | ||||
| Price To Book | 9.15 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.